DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Komoroski B, Vachharajani N, Feng Y et al.
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Clin Pharmacol Ther 2009;
85: 513-519
We do not assume any responsibility for the contents of the web pages of other providers.